🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Canada at 'crossroads' with COVID-19 case numbers rising

Published 09/22/2020, 12:43 PM
Updated 09/22/2020, 01:35 PM
© Reuters. People wait in line at a coronavirus disease (COVID-19) testing facility in Toronto.
SNY
-
MRNA
-

By Steve Scherer

OTTAWA (Reuters) - Canada is facing a surge in COVID-19 cases that risks ballooning to higher levels than were seen during the first wave of the pandemic in the spring if people do not take stringent precautions, health officials said on Monday.

"Canada is at a crossroads and individual action to reduce contact rates will decide our path," said a statement from the Public Health Agency.

According to a worst-case scenario outlined by the agency, cases could rise more than 1,000 per day for the next 10 days to 155,795 by Oct. 2, with the death toll hitting 9,300. On Monday, Canada had reported 145,415 total cases and 9,228 deaths.

Canada's chief public health officer, Theresa Tam, outlined three scenarios, with the most favorable being a "slow burn" that involves active case detection and tracing, and for individuals to take all the necessary precautions.

However, if action is not taken, the outcome could be disastrous, she said.

"With minimum controls, the virus is capable of surging into a very sharp and intense peak ... (that) could overwhelm our health system capacity and significantly impact our social and economic systems as well," she said.

Even with enhanced detection and tracing, if people do not take precautions health officials see cases "far exceeding the peak we reached in the spring," Tam said.

Tam's comments are the latest in a series of warnings from health officials across Canada about the potential spread of the disease. Authorities are particularly concerned about the rapid spread among young people.

Procurement Minister Anita Anand also announced new agreements in obtaining eventual coronavirus vaccines and a first purchase of remdesivir, an anti-viral medication produced by Gilead Sciences Inc (O:GILD).

© Reuters. People wait in line at a coronavirus disease (COVID-19) testing facility in Toronto.

Anand said Canada also announced a new agreement with Sanofi and GSK (L:GSK) for up to 72 million doses of their potential COVID-19 vaccine, and increased by up to 14 million doses a previous agreement for the Moderna (O:MRNA) vaccine.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.